Mohamad A. Salkeni

ORCID: 0000-0002-7222-1967

Also affiliated with National Cancer Institute

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 5 papers. Top paper: “A phase 2 study of anti-PD-L1 antibody (atezolizumab) in grade 2 and 3 chondrosarcoma.”.

A phase 2 study of anti-PD-L1 antibody (atezolizumab) in grade 2 and 3 chondrosarcoma.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.11528

N/A

0.208DataRank · unranked

3 citations

Anthony P. Conley, James Lin Chen, Elizabeth J. Davis, Melissa Burgess, Albiruni Ryan Abdul Razak +13 more

A phase 2 study of an anti–PD-L1 antibody (atezolizumab) in dedifferentiated chondrosarcoma.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.11533

N/A

0.104DataRank · unranked

1 citations

Brian Ko, Brian A. Van Tine, Anthony P. Conley, Elizabeth J. Davis, Melissa Burgess +12 more

Interleukin-10 in cancer immunotherapy: from bench to bedside

Trends in cancer(2023)10.1016/j.trecan.2023.05.003

N/A

0DataRank · unranked

107 citations

Aung Naing, Mohamad A. Salkeni

Phase 2 trial of TRC102 (methoxyamine HCl) with temozolomide (TMZ) in patients with granulosa cell ovarian cancer.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.5564

N/A

0DataRank · unranked

1 citations

Geraldine O’Sullivan Coyne, Jennifer Zlott, Mohamad A. Salkeni, Naoko Takebe, Ning Ma +12 more

Correction: Margaryan et al. The Stem Cell Phenotype of Aggressive Breast Cancer Cells. Cancers 2019, 11, 340

Cancers(2025)10.3390/cancers17223701

N/A

0DataRank · unranked

0 citations

Hannah Hazard‐Jenkins, Mohamad A. Salkeni, Matthew B. Smolkin, James Coad, Sijin Wen +4 more